Hong Kong, China

HUTCHMED, a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

HUTCHMED has successfully raised c US$537m (or HK$4.17bn) through its Hong Kong IPO and global offering. The new funds enable management to execute their ambitious near- and medium-term growth plans. As well as progressing the second and third wave of innovative programmes through clinical trials, the proceeds will be used to bolster the China Oncology commercial organisation and further develop the equivalent global infrastructure. A sister note detailing the recent clinical data for the key late-stage assets is published alongside this note. We upgrade our valuation to US$8.84bn (US$52.12 per ADS), £6.8bn and HK$69.0bn (802p or HK$81.30 per share) to reflect the raise and recent clinical news.

Market information



A genuinely global R&D-driven biopharma business
Lighthouse | 03 Mar 2022
Strategic collaboration for Tazverik in Greater China
Lighthouse | 10 Aug 2021
ASCO 2021: Moving towards combinations
Update | 06 Jul 2021

Recent News

SAVANNAH shows 49% ORR in high MET lung cancer
08 Aug 2022
FRESCO-2 meets primary endpoint in mCRC
08 Aug 2022
H122 interim results & business update
01 Aug 2022
Tazemetostat China bridging study in r/r FL starts
01 Aug 2022